After specialising in laparoscopy, proctology, urology, and cosmetic surgeries, Glamyo Health is now venturing into orthopaedic surgeries
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
ZY19489 is a novel anti-malarial compound active against all current clinical strains of P. falciparum and P. vivax, including drug resistant strains
The current round is led by IIFL Asset Management (IIFL AMC) along with investment from existing investors InvestCorp and Bessemer Venture Partners (BVP)
Deplesin is an add-on therapy to gold standard agents like lithium, valproic acid, and carbamazepine, supporting patients in ways that prescription medications often cannot
Up to 100 million mRNA vaccine doses could be produced in Australia each year
The company will manufacture a cancer immunotherapy product from 2022
GCC Biotech is manufacturing the kits on a public-private partnership (PPP) model
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
Subscribe To Our Newsletter & Stay Updated
